BioAtla BCAB
NASDAQ BCAB
$1.40 +0.08 (+6.06%)
At close: Sep 8, 2026 · 4:00 PM EDT

BioAtla (BCAB) Other Non-Current Assets (2020 - 2026)

BioAtla's (BCAB) quarterly Other Non-Current Assets came in at $163000.0 in Q2 2026, little changed on a YoY basis from $163000.0 in Q2 2025, and little changed quarter-over-quarter from $163000.0 in Q1 2026.

Analysis

BioAtla (BCAB) Other Non-Current Assets (2020 - 2026) Analysis & Trends

BioAtla (BCAB) has reported Other Non-Current Assets for 7 consecutive years, with $163000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non-Current Assets changed 0.0% year-over-year to $163000.0; the trailing twelve-month figure through Jun 2026 stood at $163000.0 (changed 0.0% YoY), and the FY2025 full-year result was $163000.0, changed N/A from the prior year.
  • Other Non-Current Assets was little changed at $163000.0 in Q2 2026 per BCAB's latest filing, from $163000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $163000.0 in Q2 2025 and bottomed at $154000.0 in Q1 2022.
  • Historically, Other Non-Current Assets has averaged $157285.7 across 5 years, with a median of $154000.0 in 2022.
  • The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets increased 0.65% in 2022, then fell 0.65% in 2023.
  • Over 5 years, Other Non-Current Assets stood at $154000.0 in 2022, then changed by 0.0% to $154000.0 in 2023, then changed by 0.0% to $154000.0 in 2024, then advanced by 5.84% to $163000.0 in 2025, then changed by 0.0% to $163000.0 in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods registered $163000.0, $163000.0, and $163000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Amgen 206.46 Bn 192.47 Bn 7.24 Bn 12.98 Bn
2 Gilead Sciences 179.92 Bn 176.75 Bn 6.22 Bn 4.75 Bn
3 Vertex Pharmaceuticals 131.37 Bn 123.51 Bn 2.84 Bn 1.25 Bn
4 Regeneron Pharmaceuticals 81.86 Bn 73.87 Bn 3.93 Bn 2.31 Bn
5 Argenx Se 60.29 Bn 55.10 Bn 1.37 Bn 124.00 Mn
6 Moderna 53.76 Bn 48.62 Bn 52.00 Mn 618.00 Mn
7 Alnylam Pharmaceuticals 33.16 Bn 29.85 Bn 992.69 Mn 65.13 Mn
8 Biogen 31.90 Bn 30.62 Bn 1.96 Bn 831.80 Mn
9 Roivant Sciences 29.13 Bn 29.13 Bn 1.16 Mn 29.59 Mn
10 BioAtla 2.33 Mn 2.33 Mn - 163,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 163,000.00
Mar 31, 2026 163,000.00
Dec 31, 2025 163,000.00
Sep 30, 2025 163,000.00
Jun 30, 2025 163,000.00
Mar 31, 2024 154,000.00
Dec 31, 2023 154,000.00
Sep 30, 2023 154,000.00
Jun 30, 2023 154,000.00
Mar 31, 2023 154,000.00
Dec 31, 2022 154,000.00
Sep 30, 2022 154,000.00
Jun 30, 2022 155,000.00
Mar 31, 2022 154,000.00
Dec 31, 2021 154,000.00
Sep 30, 2021 154,000.00
Jun 30, 2021 154,000.00
Mar 31, 2021 154,000.00
Dec 31, 2020 154,000.00